Drug Trial Radar · NCT00574873
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
Last checked: Nov 20, 2026Latest source record: Jan 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
502
Actual
Start
Feb 5, 2008
Primary completion
Aug 31, 2010
Study completion May 27, 2015
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- Wyeth is now a wholly owned subsidiary of Pfizer
- First posted
- Dec 17, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Two-arm, randomized, open-label trial designed to evaluate the efficacy and safety of bosutinib alone compared to imatinib alone in subjects newly diagnosed with chronic phase Chronic Myelogenous Leukemia (CML). The primary endpoint is cytogenetic response rate at one year.
Conditions
- Chronic Myeloid Leukemia
Interventions
BosutinibDrug
500 mg once daily, by mouth (tablet) with food preferably in the morning. Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
imatinibDrug
400 mg once daily, by mouth (tablet). Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Complete Cytogenetic Response (CCyR) at Year 1Time frame: Year 1 (48 weeks)
Locations
165 sites in 29 countries. Site status is shown where the registry gives one.
Pacific Cancer Medical Center Inc
Anaheim, California
Tower Cancer Research Foundation (TCRF)
Beverly Hills, California
Robert A Moss, MD, FACP, Inc
Fountain Valley, California
UCSD Medical Center-Thornton
La Jolla, California
UCSD Moores Cancer Center
La Jolla, California
UCSD Medical Center-Hillcrest
San Diego, California
Stanford Hospital and Clinics Investigational Drug Services
Stanford, California
Stanford Hospitals and Clinics
Stanford, California
Stanford University Medical Center
Stanford, California
Cancer Care Centers of Florida
Hudson, Florida
Cancer Care Centers of Florida
New Port Richey, Florida
Pasco Pinellas Cancer Center
New Port Richey, Florida
Orlando Health, Inc.
Orlando, Florida
Pasco Pinellas Cancer Center
Tarpon Springs, Florida
Northside Hospital, Inc. - GCS/Annex
Atlanta, Georgia
Indiana Blood and Marrow Transplantation Research Franciscan St. Francis Health Center Inc.
Indianapolis, Indiana
Indiana Blood and Marrow Transplantation Research
Indianapolis, Indiana
Siouxland Hematology-Oncology Associates, LLP
Sioux City, Iowa
Cancer Center of Kansas
Salinas, Kansas
Cancer Center of Kansas
Wichita, Kansas
Kentucky Cancer Clinic
Hazard, Kentucky
Center for Cancer and Blood Disorders
Bethesda, Maryland
Josephine Ford Cancer - Downriver
Brownstown, Michigan
Henry Ford Medical Center- Fairlane
Dearborn, Michigan
Henry Ford Hospital
Detroit, Michigan
Henry Ford Hospital - West Bloomfield
Detroit, Michigan
Regional Cancer Care Associates
Cherry Hill, New Jersey
Study Supplies: Regional Cancer Care Associates
Cherry Hill, New Jersey
Somerset Hematology Oncology Associates
Somerville, New Jersey
San Juan Oncology Associates
Farmington, New Mexico
Associates In Oncology and Hematology
Chattanooga, Tennessee
The University of Texas M.D. Anderson Cancer Center
Houston, Texas
Instituto Medico Especializado Alexander Fleming
Buenos Aires, Argentina
Hospital Italiano de la Plata
La Plata, Buenos Aires, Argentina
Hospital Privado de Cordoba
Córdoba, Prov. de Cordoba, Argentina
Centro de Investigaciones Oncologicas
Bahía Blanca, Provincia Buenos Aires, Argentina
Cliniques Universitaires Saint Luc
Brussels, Belgium
C.H.R.ST. - R. Fabiola (N-D)
Charleroi, Belgium
University Hospital Gent - Department of Hematology
Ghent, Belgium
Centre Hospitalier de Jolimont - Lobbes
La Louvière, Belgium
Showing 40 of 165 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.